Back to Feed
总结
诺和诺德近日在美国推出Wegovy（司美格鲁肽）的口服起始剂量版本，使部分初始用药者可选择每日服药而非每周注射。媒体称这是减重领域首批GLP-1口服产品在美进入药房的重要进展。新剂型有望提升用药便利性与依从性，同时公司以更具竞争力的定价与供货承诺争夺市场，或带动同类减重药加速布局、价格与支付方式调整，并影响未来减重药竞争格局。
正文
Starter dose of Wegovy now available as a daily pill instead of weekly injection CNN First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. CNBC A Pill Version of Wegovy Hits Pharmacies Time Magazine What to watch for in weight loss drugs in 2026: Price changes, GLP-1 pills and more NBC News Novo Nordisk launches price war over weight-loss pills Financial Times
发布时间：